Document is current
Any future updates will be listed below
-
Authors
Li, Yihao
Qiu, Xintao https://orcid.org/0000-0002-8560-7017
Wang, Xiaoqing https://orcid.org/0000-0001-7476-8889
Liu, Hui
Geck, Renee C. https://orcid.org/0000-0001-7812-7675
Tewari, Alok K. https://orcid.org/0000-0003-2617-7499
Xiao, Tengfei
Font-Tello, Alba
Lim, Klothilda
Jones, Kristen L.
Morrow, Murry
Vadhi, Raga
Kao, Pei-Lun
Jaber, Aliya
Yerrum, Smitha
Xie, Yingtian
Chow, Kin-Hoe
Cejas, Paloma
Nguyen, Quang-Dé https://orcid.org/0000-0002-9043-4413
Long, Henry W. https://orcid.org/0000-0001-6849-6629
Liu, X. Shirley https://orcid.org/0000-0003-4736-7339
Toker, Alex
Brown, Myles https://orcid.org/0000-0002-8213-1658
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-21-019)
Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 10 February 2021
Accepted: 26 September 2021
First Online: 4 November 2021
Competing interests
: M.B. is a consultant to Novartis. He receives sponsored research support from Novartis and serves on the scientific advisory boards of Kronos Bio, H3 Biomedicine and GV20 Oncotherapy. A.T. is a consultant for Oncologie and Medicxi and is on the scientific advisory board for Bertis. X.S.L. is a cofounder, board member, SAB member and consultant of GV20 Oncotherapy and its subsidiaries, a stockholder of BMY, TMO, WBA, ABT, ABBV and JNJ, and received research funding from Takeda, Sanofi, Bristol Myers Squibb and Novartis. The remaining authors declare no competing interests.
